Overview

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

Status:
Not yet recruiting

Trial end date:
2024-05-07

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the safety, efficacy and pharmacokinetics of belimumab administered in combination with background standard therapy in pediatric participants with active SLE.

Phase:

Phase 4

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Belimumab